Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
Phase I Study of Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
Sponsor: Genelux Corporation
This PHASE1 trial investigates Lung Cancer and is currently completed. Genelux Corporation leads this study, which shows 14 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Nov 2024 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
Mar 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 9 earlier versions
-
Mar 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE1
-
Feb 2022 — Mar 2022 [monthly]
Active Not Recruiting PHASE1
-
Feb 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE1
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
-
Feb 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jan 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genelux Corporation
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .